TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23592303
Drug: Raised serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raised serum level of C-reactive protein (over 240 mg/l) during the first attack
Study: 23592699
Drug: Preoperative docetaxel/platin/fluoropyrimidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative docetaxel/platin/fluoropyrimidine-based chemotherapy
Study: 23593142
Drug: ORMD-0801 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD-0801 oral insulin capsules (8 mg insulin), self-administered three times daily before meals
Study: 23593305
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of CC-chemokine ligand 21
Study: 23596180
Drug: Oral disposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disposition index
Study: 23597147
Drug: Treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treprostinil diethanolamine SR (2 mg and 4 mg doses, twice daily)
Study: 23598171
Drug: Crizotinib 280
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib 280 mg/m(2) twice daily
Study: 23602668
Drug: MEDI-534 vaccine
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-534 vaccine at 10(6)TCID50
Study: 23602777
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily with HPR (PRU ≥234)
Study: 23604435
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg isotopically labeled cyanidin-3-glucoside
Study: 23609828
Drug: HLA class
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA class I haplotype (HLA-A2) peptide vaccine
Study: 23609828
Drug: HLA class
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA class II haplotype (DR4, DP4) peptide vaccine
Study: 23610374
Drug: Virus-specific T
Normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific T cell (VST) lines administered to patients (n = 50)
Study: 23611709
Drug: Zenith p-branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zenith p-branch device (standard fenestrated endovascular graft); off-the-shelf design used for treatment.
Study: 23611902
Drug: Interactive media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive media treatment for depression (6 sessions of problem-solving therapy)
Study: 23611902
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group (no treatment for 6 weeks)
Study: 23612920
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow-derived progenitor cells (BMC)
Study: 23612920
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as patients not receiving BMC therapy)
Study: 23613128
Drug: LY6K-177 peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY6K-177 peptide vaccine emulsified with Montanide ISA 51
Study: 23613128
Drug: LY6K-177 peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY6K-177 peptide vaccine
Study: 23613521
Drug: 5-azacytidine (AZA)
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals
Study: 23615181
Drug: Oral ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ridaforolimus (40 mg QDx5/wk) combined with intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Study: 23615181
Drug: Intravenous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Study: 23617626
Drug: Intensive malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive malaria screening and prompt treatment
Study: 23617744
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy as per evidence-based guidelines for stroke prevention in AF
Study: 23620058
Drug: Alginate-encapsulated human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate-encapsulated human islet cell implants
Study: 23621514
Drug: SNS01 (Ectoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNS01 (Ectoin Rhinitis nasal spray)
Study: 23623397
Drug: Eculizumab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab 600 mg intravenous weekly for 4 weeks, 900 mg in the fifth week, and then 900 mg every 2 weeks for 48 weeks.
Study: 23623559
Drug: Sequential FISH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood cells
Study: 23624172
Drug: Alternative intervention
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative intervention focused on oral health
Study: 23624209
Drug: CD30 positive
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD30 positive cases after chemotherapy
Study: 23624209
Drug: CD30 negative
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD30 negative cases after chemotherapy
Study: 23624209
Drug: After first
Approvals — FDA: no, EMA: no, PMDA: no
Description: After first line treatment in CD30 positive cases
Study: 23624209
Drug: After first
Approvals — FDA: no, EMA: no, PMDA: no
Description: After first line treatment in CD30 negative cases
Study: 23624993
Drug: Liraglutide (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6, 1.2, or 1.8 mg daily for 12 weeks)
Study: 23626752
Drug: Moxifloxacin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin treatment
Study: 23626901
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH) therapy (0.033 mg/kg daily for 4 weeks)
Study: 23628375
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) use
Study: 23629714
Drug: Azithromycin (AZI)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZI) 500 mg once a day for 3 days
Study: 23630200
Drug: Cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (30 mg once daily in 28-day cycles)
Study: 23631460
Drug: Control (anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (anesthetic agents only)
Study: 23632474
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg once daily plus intravenous paclitaxel 80 mg m(-2) on days 1, 8, and 15 of each 28-day cycle
Study: 23632636
Drug: Palmitic acid
Normalized name: Palmitic Acid
DrugBank: Palmitic Acid (DB03796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitic acid (PA) treatment
Study: 23632636
Drug: TNFα treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFα treatment
Study: 23632636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PA and TNFα treatment
Study: 23632904
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (0.03-0.06 mg/kg/day) for >12 months (mean duration 4.1 years)
Study: 23633404
Drug: H5 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of 4, 8, 12, 16, or 24 weeks
Study: 23633404
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of H5N1 monovalent inactivated vaccine
Study: 23633404
Drug: H5 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of ≥12 weeks
Study: 23636448
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days after 7 days of pazopanib 400 mg alone.
Study: 23636448
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days after 7 days of pazopanib 800 mg alone.
Study: 23636645
Drug: Cold cap
Normalized name: 666 Cold Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cap (CC)
Study: 23636645
Drug: Cooling (PAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling (PAX and CC combined)
Study: 23636645
Drug: PAX and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAX and CC
Study: 23636668
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LDH ≥1.5 × ULN with clinical symptoms (abdominal pain, chest pain, dyspnea, hemoglobinuria)
Study: 23637051
Drug: Deferasirox administration
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox administration modes during assessment phase
Study: 23639146
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (extended-release), robust dosing, duration up to 12 months
Study: 23642526
Drug: FEC (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by weekly paclitaxel (80 mg/m(2)) with bevacizumab 10 mg/kg every 2 weeks
Study: 23642625
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with paclitaxel 135 mg/m(2) and carboplatin AUC 5 every 3 weeks for 3 cycles
Study: 23642625
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with paclitaxel/carboplatin
Study: 23643595
Drug: Copeptin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin levels <14 pmol/L combined with cardiac troponin I (cTnI) <99th percentile
Study: 23643595
Drug: Copeptin >14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin >14 pmol/L
Study: 23644082
Drug: Transcatheter valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter valve therapy (TVT) devices
Study: 23645402
Drug: Profiles of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profiles of exhaled volatile organic compounds (VOCs)
Study: 23645694
Drug: escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated dose subcutaneous alemtuzumab (starting at 30 mg three times per week, escalating to 90 mg weekly) with rituximab (375 mg/m² weekly)
Study: 23645694
Drug: escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated dose subcutaneous alemtuzumab with rituximab
Study: 23646111
Drug: Stable combination
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable combination antiretroviral therapy
Study: 23646111
Drug: Stable combination
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable combination antiretroviral therapy (Caucasian ethnicity)
Study: 23646111
Drug: Stable combination
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable combination antiretroviral therapy (Black ethnicity)
Study: 23646111
Drug: Stable combination
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable combination antiretroviral therapy (Caucasian ethnicity, demographically adjusted)
Study: 23646111
Drug: Stable combination
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable combination antiretroviral therapy (Black ethnicity, demographically adjusted)
Study: 23647688
Drug: Sustained-release acetaminophen
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release acetaminophen
Study: 23647688
Drug: Medication factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication factors (side effects, out-of-pocket costs, mode of action, treatment schedule)
Study: 23652269
Drug: Dalfampridine (0.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine (0.5-2.0 mg/kg)
Study: 23659317
Drug: Nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (125 mg/m2) and cisplatin (75 mg/m2) combination therapy
Study: 23660579
Drug: Serum-derived bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum-derived bovine immunoglobulin (SBI) 2.5 g twice daily for 8 weeks
Study: 23663091
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (3-month prospective period)
Study: 23663490
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment for bipolar disorder
Study: 23663490
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use during episodes
Study: 23664013
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) given concurrently with chemotherapy for a total of eight doses over 36 weeks.
Study: 23664013
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) combined with conventional chemotherapy.
Study: 23664414
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment for 8 weeks
Study: 23664596
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg/d for 7 days
Study: 23664596
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 4 g/day for 28 days
Study: 23664596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and fish oil for 7 days
Study: 23664596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and fish oil
Study: 23665950
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg/day on Schedule 2/2 plus S-1 (80-120 mg/day)/cisplatin 60 mg/m²
Study: 23665950
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg/day on continuous daily dosing (CDD)
Study: 23665950
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg/day on Schedule 2/2
Study: 23665950
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day on Schedule 2/2
Study: 23665950
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (sunitinib plus S-1/cisplatin)
Study: 23666316
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg QW + MTX for 36 weeks
Study: 23666573
Drug: Theophylline dosing
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline dosing regimen (exact dosage not specified)
Study: 23667266
Drug: 3-dose quadrivalent
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose quadrivalent HPV vaccine series (HPV-6, -11, -16, -18)
Study: 23667487
Drug: Lapatinib 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500 mg daily
Study: 23668924
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (mean dose 2.4±1.4 mg/24 h)
Study: 23668924
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (starting doses: 1 mg/24 h for 85% of de novo patients, 1 mg/24 h for 50% of pretreated patients, 2 mg/24 h for 40% of pretreated patients)
Study: 23669289
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) for 48 weeks
Study: 23669289
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir)
Study: 23675632
Drug: 0.25% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% miconazole nitrate ointment (7-day course)
Study: 23676114
Drug: Intravenous anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous anidulafungin for at least 5 days, optionally followed by oral voriconazole
Study: 23676114
Drug: Intravenous anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous anidulafungin
Study: 23676799
Drug: Self-empowerment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-empowerment group treatment
Study: 23676799
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy and medical examinations
Study: 23678005
Drug: Intermittent imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent imatinib (IM) therapy for 1 month on and 1 month off
Study: 23678006
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor-directed therapy)
Study: 23678376
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (50 mg in an excipient solution applied as a spray to the oropharynx)
Study: 23678376
Drug: Placebo (taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (taste excipients solution without active substance)
Study: 23680457
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g/d for 5 d followed by 5 g/d throughout the trial)
Study: 23680957
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents administered during or after the procedure
Study: 23682558
Drug: Anti-transforming growth
Normalized name: Anti-transforming growth factor-beta monoclonal antibody 2G7
DrugBank: 2G7 (DB18589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-transforming growth factor-β therapy
Study: 23684555
Drug: Two 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 150 g portions of farmed salmon per week
Study: 23685546
Drug: GSK1360707 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1360707 (novel triple reuptake inhibitor)
Study: 23686466
Drug: Adalimumab after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab after drug withdrawal and retreatment
Study: 23687088
Drug: B7-H6 induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7-H6 induction in vitro by Toll-like receptor ligands or proinflammatory cytokines
Study: 23687572
Drug: 0.50-mL dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Study: 23687572
Drug: 0.25-mL dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Study: 23688169
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 400 ug twice daily for twelve weeks
Study: 23689994
Drug: Subconjunctival Palomid
Normalized name: Palomid 529
DrugBank: Palomid 529 (DB12812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival Palomid 529 (1.9 mg)
Study: 23692690
Drug: Non-invasive foot-worn
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive foot-worn biomechanical device (AposTherapy) used daily during regular activities
Study: 23694831
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of OKA/GSK varicella vaccine
Study: 23694831
Drug: Any varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any varicella vaccine (including OKA/GSK, OKA/Merck, MMR-OKA/GSK)
Study: 23697705
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations <10 ng/mL
Study: 23697705
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥10 to <20 ng/mL
Study: 23697705
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥20 ng/mL (highest category)
Study: 23698253
Drug: Temsirolimus 15
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 15 mg IV weekly and Pazopanib 400 mg orally daily
Study: 23698253
Drug: Temsirolimus 10
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 10 mg IV weekly and Pazopanib 200 mg orally daily